Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06431932
Other study ID # Fisetin
Secondary ID 2023-506284-34-0
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date June 1, 2024
Est. completion date June 1, 2034

Study information

Verified date May 2024
Source Hvidovre University Hospital
Contact Juliette Tavenier
Phone +4538620640
Email juliette.tavenier@regionh.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The accumulation of senescent cells with age is a central mechanism that contributes to the development of chronic diseases, primarily by driving systemic chronic inflammation. Senolytic compounds such as fisetin can selectively target senescent cells for elimination and reduce multiple age-related pathologies in animal models. We will conduct a clinical trial in healthy volunteers and older patients with multiple chronic diseases. The participants will receive fisetin or placebo for two days, after which they will be examined at regular intervals for up to three months. We will investigate how fisetin is absorbed and metabolized by the body, and whether fisetin is safe. We will also identify methods to best measure the effect of fisetin on chronic inflammation, senescent cells, and general health.


Description:

The goal of this pilot trial is to conduct a controlled clinical study to gather data on the pharmacokinetic profile of fisetin and its metabolites and on the safety and tolerability of fisetin in healthy volunteers as well as in older medical patients. Furthermore, we aim to identify potential outcome measures and perform sample size calculations for these outcomes, with the intent to conduct a larger scale effect study, at later date, given the result from this pilot study suggests that this would be feasible and safe. The trial consists of: - a single-arm open-label study, in which healthy volunteers (n=20) will receive fisetin corresponding to 20 mg/kg/day for two consecutive days. - a 2-arm triple-blind randomized placebo-controlled study, in which older medical patients (n=40) will receive either: - 20 mg/kg/day fisetin for two consecutive days, or - placebo for two consecutive days. Each of the studies (open-label study and randomized placebo-controlled study) consists of three sub-studies: - Sub-study I aims to investigate the pharmacokinetic properties of fisetin and its main metabolites following oral administration at a dose of 20 mg/kg/day in healthy volunteers and in older medical patients. - Sub-study II aims to assess the safety and tolerability of oral treatment with fisetin at a dose of 20 mg/kg/day fisetin for two consecutive days in healthy volunteers and in older medical patients. - Sub-study III aims to gather representative measurements to assess the utility of inflammation, SASP, senescence, senolysis, and aging biomarkers, as well as measures of frailty, clinical parameters, physical and cognitive function, and quality of life as potential outcomes in future clinical trials; additionally, to perform sample size calculations for future trials based on these data.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date June 1, 2034
Est. primary completion date December 31, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years and older
Eligibility Healthy volunteers: Inclusion Criteria: - Aged 20-35 years - suPAR levels <3.5 ng/mL (± 15% corresponding to assay variation) - Able to cooperate cognitively - Able to read and understand Danish - Women of childbearing potential must use effective contraception Exclusion Criteria: - Body weight >100 kg - Inability to swallow pills - Pregnant and/or lactating - Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules - Presence of any condition that the investigator believes would put the subject at risk or would preclude the participant from successfully completing all aspects of the trial - Presence of known chronic diagnosis - Active acute illness - Prescribed medication, except contraceptives - Previous cancer diagnosis or treatment - Use of senolytic and other "anti-aging" supplements Older patients with multimorbidity: Inclusion Criteria: At screening #1 during hospital admission: - Acutely hospitalized medical patient - Age =65 years - suPAR >5 ng/mL (± 15% corresponding to assay variation) - Multimorbidity (=2 chronic diagnoses) - Able to cooperate cognitively - Able to read and understand Danish At screening #2 28 days after hospital discharge: - suPAR >5 ng/mL (± 15% corresponding to assay variation) Exclusion Criteria: At screening #1 during hospital admission: - Body weight >100 kg - Inability to swallow pills - Known human immunodeficiency virus infection, active hepatitis B or C infection, invasive fungal infection - Uncontrolled (as per clinical judgment) pleural/pericardial effusions or ascites - New/active invasive cancer except non-melanoma skin cancers - Active cancer treatment or disseminated cancer - Known condition associated with major immunodeficiency - Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules - Use of senolytic and other "anti-aging" supplements At screening #2 28 days after hospital discharge: - Body weight >100 kg - CRP >30 mg/L (± 15% corresponding to assay variation) - Inability to swallow pills - Presence of any condition, or abnormal routine biochemistry test, that the investigator believes would put the subject at risk or would preclude the patient from successfully completing all aspects of the trial - Unstable (as per clinical judgment) major disorders, e.g., cardiovascular, renal, endocrine, immunological, hepatic disorder, or cancer - Estimated glomerular filtration rate (eGFR) <15 ml/min/1.73 m2 or as per clinical judgment (e.g., risk of acute kidney injury) - Human immunodeficiency virus infection, known active hepatitis B or C infection, invasive fungal infection - Uncontrolled (as per clinical judgment) pleural/pericardial effusions or ascites - New/active invasive cancer except non-melanoma skin cancers - Active cancer treatment or disseminated cancer - Known condition associated with major immunodeficiency - Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules - Subjects taking strong inhibitors or inducers of CYP3A4 or as per clinical judgment - Subjects taking specified substrates with a narrow therapeutic range for CYP3A4 or as per clinical judgment - Subjects taking specified inhibitors, inducers, or substrates of CYP2D6, CYP2C9, or CYP2C8, or as per clinical judgment - Subjects regularly using drug classes or specific medications or as per clinical judgment - Use of senolytic and other "anti-aging" supplements

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Fisetin
Subjects will receive fisetin corresponding to 20 mg/kg/day for two consecutive days.
Placebo
Subjects will receive a corresponding number of placebo capsules for two consecutive days.

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Ove Andersen Mayo Clinic, University of Southern Denmark

Outcome

Type Measure Description Time frame Safety issue
Primary Population-based pharmacokinetic model for fisetin and metabolites To develop a population-based pharmacokinetic (popPK) model for fisetin and its main metabolites in healthy volunteers and older patients, covariates such as body weight, body composition, age, and CYP inducers/inhibitors will be tested for influence on interindividual variability. 24 hours
Primary Adverse events Number of participants to experience adverse events Day 1 to 3
Primary suPAR The change in plasma levels of suPAR and a sample size calculation based on these data. Day 1 to 29
Secondary Population-based PKPD model for fisetin Changes in any of the measured biomarkers and the relationship between the pharmacokinetics and pharmacodynamics of fisetin will be investigated using population PKPD modeling. 24 hours
Secondary Renal excretion of fisetin and its main metabolites Urinary levels of fisetin and its main metabolites 24 hours
Secondary Symptoms and adverse events Number of participants to experience symptoms and clinically significant changes in vital signs (i.e., blood pressure, pulse). Day 1 to 3
Secondary SASP factors and inflammation markers The change in plasma levels of SASP factors and inflammation markers (e.g., cytokines, chemokines, proteases, growth factors). Healthy volunteers: day 1, 2, 29. Older patients: day 1, 2, 8, 15, 29, 57, 84.
Secondary Senescence The change in expression levels of senescence markers (e.g., p16INK4a, p21CIP1/WAF1, SA-B-gal) in immune cells and tissue biopsies (skin and adipose tissue). Healthy volunteers: day 1, 29. Older patients: day 1, 8, 15, 29, 84.
Secondary Senolysis The change in expression levels of senolysis markers (e.g., leukotriene B4, dihomo-15d-PGJ2 (oxylipin or 1a,1b-dihomo-15-deoxy-D12,14-prostaglandin J2), and 15-Deoxy-delta 12, 14-prostaglandin J2). Healthy volunteers: day 1, 2, 29. Older patients: day 1, 2, 8, 15, 29, 84.
Secondary Aging markers The change in plasma levels of aging markers (e.g., a-klotho, fibroblast growth factor 21). Healthy volunteers: day 1, 2, 29. Older patients: day 1, 2, 8, 15, 29, 57, 84.
Secondary Clinical markers The change in levels of routine biochemistry markers (e.g., alanine aminotransferase, albumin, alkaline phosphatase, bilirubin, blood urea nitrogen, coagulation factors II, VII and X and International Normalized Ratio, CRP, creatinine, hemoglobin, lactate dehydrogenase, mean corpuscular hemoglobin concentration, mean corpuscular volume, neutrophils, potassium, sodium, thrombocytes, white blood cell count, cholesterol (total, low-density lipoproteins, high-density lipoproteins), triglycerides, and hemoglobin A1c). Healthy volunteers: day 1, 2, 29. Older patients: day 1, 2, 8, 15, 29, 57, 84.
Secondary Frailty Index OutRef The change in frailty status calculated as Frailty Index OutREF (FI-OutRef). Healthy volunteers: day 1, 29. Older patients: day 1, 2, 8, 15, 29, 57, 84.
Secondary Frailty Index The change in frailty status calculated using a modified version of Fried frailty criteria. Healthy volunteers: day 1, 29. Older patients: day 1, 2, 8, 15, 29, 57, 84.
Secondary Physical function The change in physical function (e.g., gait speed, hand grip strength, chair stand test, balance). Healthy volunteers: day 1, 29. Older patients: day 1, 29, 84.
Secondary Cognitive function (Montreal Cogntive Assessment) The change in cognitive function assessed using the MoCA score (0-30 with higher scores representing better cognitive function). Healthy volunteers: day 1, 29. Older patients: day 1, 29, 84.
Secondary Cognitive function (Digit Symbol Substitution Test) The change in cognitive function assessed using the Digit Symbol Substitution Test (number of correct symbols). Healthy volunteers: day 1, 29. Older patients: day 1, 29, 84.
Secondary Quality of life The change in quality of life assessed using the EuroQol-5D-5L (index value and VAS scale 0-100; with higher scores representing better quality of life). Healthy volunteers: day 1, 29. Older patients: day 1, 29, 84.
Secondary Self-rated health The change in self-rated health (score 1-5; 1:"excellent", 2:"very good", 3:"good", 4:"fair", or 5:"bad"). Healthy volunteers: day 1, 29. Older patients: day 1, 29, 84.
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1